Press releaseGlobe Newswire
Vaccinex
VCNX · OTC
$0.7001−$0.2999 (−29.99%)TodayMarket closed ·
No price history for this range.
Latest news
- Press releaseGlobe Newswire
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
- Press releaseGlobe Newswire
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease
- Press releaseGlobe Newswire
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
- Press releaseGlobe Newswire
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
- NewsVaishali Prayag
Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?
- NewsAvi Kapoor
Crude Oil Down Over 1%; US Industrial Production Declines In November
- NewsAvi Kapoor
Dow Dips Over 200 Points; US Retail Sales Top Estimates
- Press releaseGlobe Newswire
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
- Press releaseGlobe Newswire
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain
- Press releaseGlobe Newswire
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024
- NewsDylan Berman
What's Going On With Vaccinex Stock Wednesday?
- NewsAvi Kapoor
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
- NewsAvi Kapoor
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.